Shine-On Biomedical Co.

What Shine-On Biomedical Co. does

Shine-On Biomedical Co., Ltd. (DBA: Shine-On BioMedical) is a Taiwan-based biopharmaceutical company founded on April 6, 2021 by Dr. Chiu-Chin Huang. The company has been listed on the Emerging Stock Market of Taipei Exchange (code 6926) since November 2022 and is headquartered in Taichung City, Taiwan. It operates as a pre-revenue drug developer targeting first-in-human novel therapeutics for oncology and central nervous system disorders, and the Cortellis database ranks it among the top ten companies globally for developing next-generation targeted exosome therapeutics and multi-specific antibody drugs.

The company's pipeline rests on two proprietary technology platforms. The first is an HLA-G targeted exosome platform (SOB100) that engineers exosomes with HLA-G-specific nanoantibodies to precisely navigate to tumor cells expressing HLA-G. Derived candidates include SOB101 (exosomal doxorubicin for breast, ovarian, pancreatic, lung cancers and brain tumors, with preclinical data indicating no cardiotoxicity), SOB102 (exosomal microRNA for drug-resistant glioblastoma multiforme, with confirmed blood-brain barrier passage in animal studies), and SOB201 (genetically engineered stem cell-derived exosomes for post-stroke tissue repair). The second platform is a Trispecific T cell engager antibody platform producing SOA101 (nanobody-based trispecific antibody simultaneously targeting PD-L1 and HLA-G while engaging T cells, achieving three world-firsts) and SOA201 (EphA10-trispecific engager activating both NK and T cells for women's cancers). FDA Pre-IND consultations were completed for SOA101 in January 2024 and for SOB101 in March 2024.

Shine-On Biomedical monetizes through two intended channels. Future pharmaceutical revenue will derive from product sales to healthcare providers, hospitals, and cancer treatment centers upon regulatory approval, with development and manufacturing executed via international CDMO/CRO partners. Interim commercial activity is in cosmetic-grade exosome ingredients SOC101 (ExDeer, antler stem cell exosomes) and SOC102 (ExUmbilical, umbilical cord stem cell exosomes), both holding INCI accreditation that enables global commercial availability in cosmetic and skincare markets. The company holds technical patents across its exosome and multi-specific antibody portfolio and collaborates with worldwide research institutes and expert consulting groups for novel biological drug development.

Name

Shine-On Biomedical Co.

Legal name

Shine-On Biomedical Co., Ltd.

Website

https://en.shineon-bio.com

Company type

Public

Founded year

2021

Operating status

Ipo

Short description

Shine-On Biomedical is a Taiwan-based, Taipei Exchange-listed pre-revenue biopharmaceutical company developing first-in-class oncology and CNS therapeutics using two proprietary platforms: HLA-G targeted exosomes for drug delivery and trispecific T cell engager antibodies, with an adjacent cosmetic-grade exosome ingredients business.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Exosome drug delivery
• Trispecific antibody therapy
• Oncology drug development
• Targeted cancer therapeutics
• Biopharmaceutical pipeline development

Headquarters

HQ city

Taichung

HQ country

Taiwan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Novel Drug Development and Commercialization: Pre-revenue biopharmaceutical company developing first-in-human novel drugs based on targeted exosome and trispecific antibody platforms. Revenue will be generated through pharmaceutical product sales upon regulatory approval and commercialization of pipeline candidates including SOB100-series, SOB200-series, SOA100, and SOA201 for cancer treatment.
2. Exosome-Derived Cosmetic Ingredients: Commercialization of exosome-derived products SOC101 (ExDeer - antler stem cell exosomes) and SOC102 (ExUmbilical - umbilical cord stem cell exosomes) with INCI accreditation enabling global commercial availability in cosmetic and skincare markets.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Shine-On Biomedical is a pre-revenue biopharmaceutical developer building first-in-human cancer therapeutics based on two proprietary platforms: HLA-G targeted exosome drug delivery and nanobody-based trispecific T cell engager antibody. Its pipeline includes HLA-G targeted exosomal drugs (SOB101 doxorubicin, SOB102 microRNA for glioblastoma, SOB201 stem-cell exosomes for stroke), trispecific antibody candidates (SOA101 Nb-TriTE, SOA201 EphA10 engager), and INCI-registered exosome-derived cosmetic ingredients SOC101 (ExDeer) and SOC102 (ExUmbilical).

Product overview

Shine-On Biomedical Co. is a biotech company developing first-in-human novel drugs based on two innovative technology platforms: 'Targeted exosome for drug delivery' and 'Trispecific T cell engager antibody'. The product portfolio includes: (1) HLA-G targeted exosome platform (SOB100) with three derived exosomal drugs - SOB101 (doxorubicin delivery for multiple cancers), SOB102 (microRNA delivery for brain tumors), and SOB201 (genetically engineered stem cell-derived exosomes for stroke treatment); (2) Trispecific T cell engager antibody platform producing SOA101 (Nb-TriTE for multiple cancers) and SOA201 (EphA10-trispecific for women's cancers); and (3) Exosome-derived cosmetic products SOC101 (ExDeer) and SOC102 (ExUmbilical). According to Cortellis database, ShineOn is ranked among the top ten companies worldwide for developing next-generation targeted exosome therapeutic drugs and multi-specific antibody drugs.

Differentiator

Problem solved

Functional benefit

Brands

• ExDeer: Trademark for SOC101 - antler stem cell exosomes, accredited by International Nomenclature of Cosmetic Ingredients (INCI) as the first category of INCI in the world.
• ExUmbilical

Products and services

• SOB100: HLA-G targeted exosome (αHLA-G exo) First proprietary HLA-G targeted exosome platform for novel drug development, using HLA-G-specific nanoantibodies to precisely navigate exosomes to tumor cells; HLA-G serves as both an immune checkpoint and neo tumor target highly overexpressed on various tumor cells. Targeted at biopharmaceutical partners and eventual oncology healthcare providers.
• SOB101: HLA-G targeted exosomal doxorubicin First broad-spectrum exosome-based anti-cancer drug using HLA-G targeted exosomes to deliver doxorubicin for treatment of breast cancer, ovarian cancer, pancreatic cancer, lung cancer, and brain tumor; preclinical studies demonstrated greater effectiveness and safety than doxorubicin and liposomal doxorubicin with no cardiotoxicity observed.
• SOB102: HLA-G targeted exosomal microRNA Second broad-spectrum exosome-based anti-cancer drug using HLA-G targeted exosomes to deliver nucleic acids for treatment of refractory/resistant brain tumors such as glioblastoma multiforme (GBM); animal experiments confirmed capability to pass through the blood-brain barrier.
• SOB201: Genetically engineered stem cell-derived exosomes Genetically engineered stem cell-derived exosome using genetic engineering to allow gene sequences including targeted antibodies and growth factors to be expressed in mesenchymal stem cells; aimed to treat injured tissues after stroke by reducing inflammatory responses at the injured site and promoting generation of brain neurons.
• SOA101: Nanobody-based trispecific antibody T cell engager (Nb-TriTE) First broad-spectrum trispecific antibody drug for treatment of lung cancer, colorectal cancer, breast cancer, head and neck cancer, and ovarian cancer; achieves three world-firsts (dual immune checkpoint inhibitor for cancer treatment, trispecific antibody drug targeting HLA-G, and nanobody-based tri-specific antibody drug against cancer).
• SOA201: EphA10-trispecific immune cell engager antibody World's first trispecific antibody with EphA10 as tumor target that activates both natural killer cells and T-cells; current development aims to treat women's cancers including breast cancer (including triple-negative breast cancer) and ovarian cancer.
• SOC101 (ExDeer) Antler stem cell exosomes accredited by the International Nomenclature of Cosmetic Ingredients (INCI) as the first category of INCI in the world, enabling global commercial availability in cosmetic and skincare markets under the trademark ExDeer.
• SOC102 (ExUmbilical) Umbilical cord stem cell exosomes granted an INCI number globally, currently undergoing development under the trademark ExUmbilical for use as an active ingredient in cosmetic and skincare products.

Quantifiable outcome

• Top 10 globally in exosome-based biotech company for new drug development
• +3 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Worldwide Renowned Research InstitutescoreStrategic or Co-development PartnerShineOn collaborates with worldwide renowned research institutes for novel biological drug development to treat cancer patients
• International CDMO/CRO CompaniescoreImplementation/ SI/ Consulting PartnerCollaboration with international capable CDMO (Contract Development and Manufacturing Organization) and CRO (Contract Research Organization) companies for drug development and manufacturing services
• Professional Expert Consulting GroupsminorImplementation/ SI/ Consulting PartnerPartnership with professional expert consulting groups to support new biological drug development
• 中國醫藥大學附設醫院 (China Medical University Hospital)minorStrategic or Co-development PartnerCollaboration with China Medical University Hospital and other biomedical partners to host charity events for children, including visits to proton therapy center
• 長聖國際生技 (St. Sheng International Biotechnology)minorStrategic or Co-development PartnerBiomedical enterprise partner for joint charity activities with China Medical University Hospital
• 長佳智能 (長佳智能)minorStrategic or Co-development PartnerBiomedical enterprise partner for joint charity activities

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Market position

Competitive moat3 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shine-On Biomedical Co.